tamibarotene has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Egusa, C; Kato, Y; Maeda, T; Tsuboi, R | 1 |
1 other study(ies) available for tamibarotene and Cutaneous T-Cell Lymphoma
Article | Year |
---|---|
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzoates; Cell Line, Tumor; Cell Proliferation; Female; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Histones; Humans; Lymphoma, T-Cell, Cutaneous; Mice; Mice, Inbred NOD; Mice, SCID; Promoter Regions, Genetic; Pyridines; Receptors, Retinoic Acid; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2016 |